An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Phase of Trial: Phase III
Latest Information Update: 28 Mar 2019
Price : $35 *
At a glance
- Drugs Reslizumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Teva Branded Pharmaceutical Products R&D
- 19 Mar 2019 Status changed to discontinued.
- 29 Nov 2018 Status has been changed to completed.
- 19 Apr 2018 This trial has been discontinued in Poland (end date: 2018-01-24) according to European Clinical Trials Database record.